| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 技术授权许可(元) | 1,090,364.80 | 2,356,368.70 | 2,900,445.70 | 6,622,425.52 | 3,875,496.93 |
| 销售商品(元) | 397,647,375.90 | - | 292,529,501.33 | - | 235,582,043.18 |
| 西达本胺片销售(元) | - | 499,541,051.62 | - | 466,605,983.75 | - |
| 西格列他钠销售收入(元) | - | 140,159,890.19 | - | 42,247,926.67 | - |
| 其他(元) | 517,120.84 | 2,444,251.40 | 6,730,562.02 | 2,097,311.10 | - |
| 营业成本(元) | |||||
| 技术授权许可(元) | - | - | - | - | - |
| 销售商品(元) | 49,439,730.14 | - | 33,253,547.67 | - | - |
| 西达本胺片销售(元) | - | 33,611,091.03 | - | 18,245,099.91 | - |
| 西格列他钠销售收入(元) | - | 46,666,054.89 | - | 35,725,607.44 | - |
| 其他(元) | 1,169,982.69 | 1,818,446.55 | 3,262,796.80 | 991,292.61 | - |
| 毛利(元) | |||||
| 技术授权许可(元) | 1,090,364.80 | 2,356,368.70 | 2,900,445.70 | 6,622,425.52 | - |
| 销售商品(元) | 348,207,645.76 | - | 259,275,953.66 | - | - |
| 西达本胺片销售(元) | - | 465,929,960.59 | - | 448,360,883.84 | - |
| 西格列他钠销售收入(元) | - | 93,493,835.30 | - | 6,522,319.23 | - |
| 其他(元) | -652,861.85 | 625,804.85 | 3,467,765.22 | 1,106,018.49 | - |
| 毛利率(%) | |||||
| 技术授权许可(%) | - | - | - | - | - |
| 销售商品(%) | 87.57 | - | 88.63 | - | - |
| 西达本胺片销售(%) | - | 93.27 | - | 96.09 | - |
| 西格列他钠销售收入(%) | - | 66.71 | - | 15.44 | - |
| 其他(%) | -126.25 | 25.60 | 51.52 | 52.74 | - |
| 收入构成(%) | |||||
| 技术授权许可(%) | 0.27 | 0.37 | 0.96 | 1.28 | 1.62 |
| 销售商品(%) | 99.60 | - | 96.81 | - | 98.38 |
| 西达本胺片销售(%) | - | 77.51 | - | 90.15 | - |
| 西格列他钠销售收入(%) | - | 21.75 | - | 8.16 | - |
| 其他(%) | 0.13 | 0.38 | 2.23 | 0.41 | - |
| 毛利构成(%) | |||||
| 技术授权许可(%) | 0.31 | 0.42 | 1.09 | 1.43 | - |
| 销售商品(%) | 99.87 | - | 97.60 | - | - |
| 西达本胺片销售(%) | - | 82.85 | - | 96.92 | - |
| 西格列他钠销售收入(%) | - | 16.62 | - | 1.41 | - |
| 其他(%) | -0.19 | 0.11 | 1.31 | 0.24 | - |